UCL 2077

UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC50 = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization[1]. UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels[2].

Product Specifications

CAS Number

[918311-87-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ucl-2077.html

Purity

98.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C1(CNC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=CC=CN=C1

Molecular Formula

C25H22N2

Molecular Weight

350.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Shah MM, et al. Enhancement of hippocampal pyramidal cell excitability by the novel selective slow-afterhyperpolarization channel blocker 3- (triphenylmethylaminomethyl) pyridine (UCL2077) . Mol Pharmacol. 2006 Nov;70 (5) :1494-502.|[2]Soh H, et al. The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels. Mol Pharmacol. 2010 Dec;78 (6) :1088-95.